A novel role for tissue factor pathway inhibitor-2 in the therapy of human esophageal carcinoma

Human Gene Therapy

Volumn 20, Issue 1, 2009, Pages 41-49

  Ran, Yuliang ^a   Pan, Jian ^a   Hu, Hai ^a   Zhou, Zhuan ^a   Sun, Lichao ^a   Peng, Liang ^a   Yu, Long ^a   Sun, Lixin ^a   Liu, Jun ^a   Yang, Zhihua ^a,b  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; PLACENTA PROTEIN 5; RECOMBINANT PLACENTA PROTEIN 5; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ESOPHAGUS CARCINOMA; FEMALE; GENE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; NUDE MOUSE; PLACENTA PROTEIN 5 GENE; PROTEIN FUNCTION;

ANIMALS; CARCINOMA; CELL LINE, TUMOR; DOWN-REGULATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GLYCOPROTEINS; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT PROTEINS;

EID: 58849121776     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2008.129     Document Type: Article

References (34)

1. Blindt, R., Vogt, F., Lamby, D., Zeiffer, U., Krott, N., Hilger-Eversheim, K., Hanrath, P., Vom Dahl, J., and Bosserhoff, A.K. (2002). Characterization of differential gene expression in quiescent and invasive human arterial smooth muscle cells. J. Vasc. Res. 39, 340-352.
2. Chand, H.S., Schmidt, A.E., Bajaj, S.P., and Kisiel, W. (2004). Structure-function analysis of the reactive site in the first Kunitz-type domain of human tissue factor pathway inhibitor-2. J. Biol. Chem. 279, 17500-17507.
3. Choi, M.S., Parikh, K., Saxena, A., and Chilukuri, N. (2007). Protective effects of recombinant Kunitz-domain 1 of human tissue factor pathway inhibitor-2 against 2-chloroethyl ethyl sulfide toxicity in vitro. Eplasty 8, e3.
4. Enzinger, P.C., and Mayer, R.J. (2003). Esophageal cancer. N. Engl. J. Med. 349, 2241-2252.
5. Furihata, T., Sakai, T., Kawamata, H., Omotehara, F., Shinagawa, Y., Imura, J., Ueda, Y., Kubota, K., and Fujimori, T. (2001). A new in vivo model for studying invasion and metastasis of esophageal squamous cell carcinoma. Int. J. Oncol. 19, 903-907.
6. George, J., Gondi, C.S., Dinh, D.H., Gujrati, M., and Rao, J.S. (2007). Restoration of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis. Clin. Cancer Res. 13, 3507-3517.
7. Golino, P., Forte, L., and De Rosa, S. (2004). Inhibition of the tissue factor coagulation pathway. Curr. Vasc. Pharmacol. 2, 319-327.
8. Guo, H., Lin, Y., Zhang, H., Liu, J., Zhang, N., Li, Y., Kong, D., Tang, Q., and Ma, D. (2007). Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells. BMC Mol. Biol. 8, 110.
9. Herman, M.P., Sukhova, G.K., Kisiel, W., Foster, D., Kehry, M.R., Libby, P., and Schonbeck, U. (2001). Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J. Clin. Invest. 107, 1117-1126.
10. Hube, F., Reverdiau, P., Iochmann, S., Rollin, J., Cherpi-Antar, C., and Gruel, Y. (2003). Transcriptional silencing of the TFPI-2 gene by promoter hypermethylation in choriocarcinoma cells. Biol. Chem. 384, 1029-1034.
11. Imai, K., Nakata, K., Kawai, K., Hamano, T., Mei, N., Kasai, H., and Okamoto, T. (2005). Induction of OGG1 gene expression by HIV-1 Tat. J. Biol. Chem. 280, 26701-26713.
12. Ivanciu, L., Gerard, R.D., Tang, H., Lupu, F., and Lupu, C. (2007). Adenovirus-mediated expression of tissue factor pathway inhibitor-2 inhibits endothelial cell migration and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 27, 310-316.
13. Izumi, H., Takahashi, C., Oh, J., and Noda, M. (2000). Tissue factor pathway inhibitor-2 suppresses the production of active matrix metalloproteinase-2 and is down-regulated in cells harboring activated ras oncogenes. FEBS Lett. 481, 31-36.
14. Jiang, P., Watanabe, H., Okada, G., Ohtsubo, K., Mouri, H., Tsuchiyama, T., Yao, F., and Sawabu, N. (2006). Diagnostic utility of aberrant methylation of tissue factor pathway inhibitor 2 in pure pancreatic juice for pancreatic carcinoma. Cancer Sci. 97, 1267-1273.
15. Kast, C., Wang, M., and Whiteway, M. (2003). The ERK/MAPK pathway regulates the activity of the human tissue factor pathway inhibitor-2 promoter. J. Biol. Chem. 278, 6787-6794.
16. Konduri, S.D., Rao, C.N., Chandrasekar, N., Tasiou, A., Mohanam, S., Kin, Y., Lakka, S.S., Dinh, D., Olivero, W.C., Gujrati, M., Foster, D.C., Kisiel, W., and Rao, J.S. (2001a). A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion. Oncogene 20, 6938-6945.
17. Konduri, S.D., Tasiou, A., Chandrasekar, N., and Rao, J.S. (2001b). Overexpression of tissue factor pathway inhibitor-2 (TFPI-2), decreases the invasiveness of prostate cancer cells in vitro. Int. J. Oncol. 18, 127-131.
18. Konduri, S.D., Srivenugopal, K.S., Yanamandra, N., Dinh, D.H., Olivero, W.C., Gujrati, M., Foster, D.C., Kisiel, W., Ali-Osman, F., Kondraganti, S., Lakka, S.S., and Rao, J.S. (2003). Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells. Oncogene 22, 4509-4516.
19. Kong, D., Ma, D., Bai, H., Guo, H., Cai, X., Mo, W., Tang, Q., and Song, H. (2004). Expression and characterization of the first Kunitz domain of human tissue factor pathway inhibitor-2. Biochem. Biophys. Res. Commun. 324, 1179-1185.
20. Nobeyama, Y., Okochi-Takada, E., Furuta, J., Miyagi, Y., Kikuchi, K., Yamamoto, A., Nakanishi, Y., Nakagawa, H., and Ushijima, T. (2007). Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int. J. Cancer 121, 301-307.
21. Parkin, D.M. (2001). Global cancer statistics in the year 2000. Lancet Oncol. 2, 533-543.
22. Pawlak, K., Pawlak, D., and Mysliwiec, M. (2004). Extrinsic coagulation pathway activation and metalloproteinase-2/TIMPs system are related to oxidative stress and atherosclerosis in hemodialysis patients. Thromb. Haemost. 92, 646-653.
23. Rao, C.N., Liu, Y.Y., Peavey, C.L., and Woodley, D.T. (1995). Novel extracellular matrix-associated serine proteinase inhibitors from human skin fibroblasts. Arch. Biochem. Biophys. 317, 311-314.
24. Rao, C.N., Cook, B., Liu, Y., Chilukuri, K., Stack, M.S., Foster, D.C., Kisiel, W., and Woodley, D.T. (1998). HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI. Int. J. Cancer 76, 749-756.
25. Rao, C.N., Reddy, P., Reeder, D.J., Liu, Y., Stack, S.M., Kisiel, W., and Woodley, D.T. (2000). Prokaryotic expression, purification, and reconstitution of biological activities (Antiprotease, antitumor, and heparin-binding) for tissue factor pathway inhibitor-2. Biochem. Biophys. Res. Commun. 276, 1286-1294.
26. Rollin, J., Iochmann, S., Blechet, C., Hube, F., Regina, S., Guyetant, S., Lemarie, E., Reverdiau, P., and Gruel, Y. (2005). Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Br. J. Cancer 92, 775-783.
27. Rollin, J., Regina, S., Vourc'h, P., Iochmann, S., Blechet, C., Reverdiau, P., and Gruel, Y. (2007). Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer 56, 273-280.
28. Sato, N., Parker, A.R., Fukushima, N., Miyagi, Y., Iacobuzio-Donahue, C.A., Eshleman, J.R., and Goggins, M. (2005). Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene 24, 850-858.
29. Shinoda, E., Yui, Y., Hattori, R., Tanaka, M., Inoue, R., Aoyama, T., Takimoto, Y., Mitsui, Y., Miyahara, K., Shizuta, Y., and Sasayama, S. (1999). Tissue factor pathway inhibitor-2 is a novel mitogen for vascular smooth muscle cells. J. Biol. Chem. 274, 5379-5384.
30. Steiner, F.A., Hong, J.A., Fischette, M.R., Beer, D.G., Guo, Z.S., Chen, G.A., Weiser, T.S., Kassis, E.S., Nguyen, D.M., Lee, S., Trepel, J.B., and Schrump, D.S. (2005). Sequential 5-aza-2′-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. Oncogene 24, 2386-2397.
31. Sun, Y., Xie, M., Liu, M., Jin, D., and Li, P. (2006). Growth suppression of human laryngeal squamous cell carcinoma by adenovirus-mediated tissue factor pathway inhibitor gene 2. Laryngoscope 116, 596-601.
32. Udagawa, K., Miyagi, Y., Hirahara, F., Miyagi, E., Nagashima, Y., Minaguchi, H., Misugi, K., Yasumitsu, H., and Miyazaki, K. (1998). Specific expression of PP5/TFPI2 mRNA by syncytiotrophoblasts in human placenta as revealed by in situ hybridization. Placenta 19, 217-223.
33. Wong, C.M., Ng, Y.L., Lee, J.M., Wong, C.C., Cheung, O.F., Chan, C.Y., Tung, E.K., Ching, Y.P., and Ng, I.O. (2007). Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 45, 1129-1138.
34. Yanamandra, N., Kondraganti, S., Gondi, C.S., Gujrati, M., Olivero, W.C., Dinh, D.H., and Rao, J.S. (2005). Recombinant adeno-associated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line. Int. J. Cancer 115, 998-1005.